MarketPulse

metabolic diseases

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Nxera Pharma Hits Second Eli Lilly Milestone in Metabolic Disease Push

Nxera Pharma achieves second milestone with Eli Lilly validating its GPCR-targeting platform. Deal includes $694M in potential payments plus royalties.
LLYdiabetesdrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Eli Lilly Acquires Centessa Pharmaceuticals in Sleep-Wake Drug Push

Eli Lilly acquires Centessa Pharmaceuticals, developer of OX2R agonists for sleep disorders co-created with Nxera Pharma, which retains milestone payments and royalties.
LLYCNTAacquisitiondrug discovery
The Motley FoolThe Motley Fool··Eric Trie

ORBIMED Advisors Reduces Terns Pharma Position Despite 858% Annual Gain

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.
LLYTERNEWvaluationbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aardvark Therapeutics Issues 152K Stock Options to New Hires

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.
AARDclinical-stagebiopharmaceutical